Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues

Mon, 11/11/2019 - 7:52pm

TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which...

      Related Stories 

Results Position Esaxerenone For Japan Diabetic Nephropathy Filing

Mon, 11/11/2019 - 7:09pm

New top-line results from Japanese study set stage for submission of esaxerenone in additional high-need indication.

      Related Stories 

Lupin Offloads Kyowa Pharma For $525m But Not Exiting Japan

Mon, 11/11/2019 - 5:04pm

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma...

      Related Stories 

Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future

Mon, 11/11/2019 - 3:51pm

Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take...

      Related Stories 

Allena Bets On Its Kidney Stone Treatment Despite Placebo Concerns

Mon, 11/11/2019 - 11:18am

Execs are hoping having positive results in two studies will help raise funds for continued development. But high placebo results...

      Related Stories 

Orphan Drug Access: One-Third Of US Coverage Decisions Involve Restrictions, Study Finds

Mon, 11/11/2019 - 9:54am

Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more...

      Related Stories 

ASLAN Falls As TreeTopp BTC Study Fails

Mon, 11/11/2019 - 7:20am

ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and...

      Related Stories 

GW Gets Two Cannabis-Based Meds Backed By NICE

Mon, 11/11/2019 - 5:40am

Two cannabis-based drugs developed by GW Pharmaceuticals have been approved for use on the NHS in England for the first...

      Related Stories 

Pipeline Watch: Phase III Readouts For Ibrexafungerp, Reloxaliase

Mon, 11/11/2019 - 2:51am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Lupin Q2 Hit By US Settlement, Japan Injectables Selloff

Sun, 11/10/2019 - 9:14pm

Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit...

      Related Stories 

Ninlaro Positive In Non-Transplant MM Maintenance

Sun, 11/10/2019 - 7:56pm

Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive...

      Related Stories 

Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated

Sun, 11/10/2019 - 5:07pm

Patient-reported outcomes indicate patients don’t see itch as a major quality-of-life factor. Intercept also reports that adding earlier-stage patients to...

      Related Stories 

Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds

Fri, 11/08/2019 - 1:14pm

Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series...

      Related Stories 

Roll Over Yamanaka: Meet The Cell Therapy Company Bypassing iPSCs

Fri, 11/08/2019 - 11:37am

Emerging Company Profile: Horizon Discovery’s former CEO Darrin Disley talks to Scrip about the importance of Mogrify’s revolutionary platform for...

      Related Stories 

Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval

Fri, 11/08/2019 - 9:27am

Biotech plans to file its first-in-class triterpenoid agent for approval in 2020 following a second Phase III study in acute...

      Related Stories 

Ambitious AB Science Gets Masitinib Win For Severe Asthma

Fri, 11/08/2019 - 6:14am

Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes...

      Related Stories 

Pages